ERT is primarily used in clinical drug development. With this acquisition, ERT will now provide electronic clinical outcome assessments and patient engagement solutions to customers in the biopharmaceutical industry. ERT’s ultimate business goal is to minimize risk for clinical research, in an effort to quickly and safely roll out new clinical treatments.
Financial terms of the transaction were not disclosed.
More articles on health IT:
AHA endorses Teladoc
Philips to advance cancer treatment with New York Medical College collaboration
Henry Ford Hospital leverages 3-D imaging for improved cardiac outcomes
